Current progress of CDC20 in cancer development and targeting CDC20 for cancer therapy
Carcinogenesis · 2026
DOI: 10.1093/carcin/bgag021 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Carcinogenesis, 2026. Verfasst von Yingtong Chen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Lymphoma Research Center, Peking University Third Hospital, 49 Huayuan North Road, Haidian District, Beijing 100191, China. Hauptthemen laut MEDLINE: Cdc20 Proteins, Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 185 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Beijing Municipal Natural Science Foundation, Beijing Municipal Health Commission.
Abstract (Originalsprache)
Cell division cycle 20 homolog (CDC20), a critical substrate-recruiting subunit of the anaphase-promoting complex/cyclosome (APC/C), binds to APC/C to form the active APC/C-CDC20 complex, which regulates the degradation of key cell cycle substrates to ensure accurate and timely mitotic progression. Accumulating evidence demonstrates that CDC20 functions as an oncogenic factor, with its overexpression observed in various malignancies. Its dysregulation is closely associated with tumor initiation, progression, drug resistance, and poor clinical outcomes, underscoring its potential as a therapeutic target in anti-cancer strategies. In this review, we describe the biological functions of CDC20 in cancers, discuss its role and underlying mechanisms in solid tumors and hematological malignancies, and elucidate currently reported CDC20-targeted inhibitors along with their clinical benefits and challenges. By emphasizing the oncogenic significance of CDC20, we propose that the development of specific, safe, and potent CDC20 inhibitors could provide a promising therapeutic approach for cancer patients exhibiting CDC20 overexpression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Lymphoma Research Center, Peking University Third Hospital, 49 Huayuan North Road, Haidian District, Beijing 100191, China.
ORCID-Profile: Yingtong Chen, Shuang Gao, Ping Yang, Shuozi Liu, Weilong Zhang, Jing Wang, Hongmei Jing
Förderung
- National Natural Science Foundation of China
- Beijing Municipal Natural Science Foundation
- Beijing Municipal Health Commission
Zitieren
APA
Chen, Y., Gao, S., Yang, P., Liu, S., Zhang, W., Wang, J., & Jing, H. (2026). Current progress of CDC20 in cancer development and targeting CDC20 for cancer therapy. Carcinogenesis. https://doi.org/10.1093/carcin/bgag021
Vancouver
Chen Y, Gao S, Yang P, Liu S, Zhang W, Wang J, et al. Current progress of CDC20 in cancer development and targeting CDC20 for cancer therapy. Carcinogenesis. 2026. doi:10.1093/carcin/bgag021
BibTeX
@article{Chen2026,
author = {Chen, Yingtong and Gao, Shuang and Yang, Ping and Liu, Shuozi and Zhang, Weilong and Wang, Jing and Jing, Hongmei},
title = {Current progress of CDC20 in cancer development and targeting CDC20 for cancer therapy},
journal = {Carcinogenesis},
year = {2026},
doi = {10.1093/carcin/bgag021}
}
EUVIMED